OM LAWSUIT ALERT: Levi & Korsinsky Notifies Outset Medical, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

July 27, 2022 9:47 AM EDT | Source: Levi & Korsinsky, LLP

New York, New York--(Newsfile Corp. - July 27, 2022) - Levi & Korsinsky, LLP notifies investors in Outset Medical, Inc. ("Outset Medical" or the "Company") (NASDAQ: OM) of a class action securities lawsuit.

The lawsuit on behalf of Outset Medical investors has been commenced in the the United States District Court for the Northern District of California. This lawsuit is on behalf of all persons or entities who purchased Outset Medical common stock between September 15, 2020, and June 13, 2022. Follow the link below to get more information and be contacted by a member of our team:

https://www.zlk.com/pslra-1/outset-medical-inc-information-request-form?prid=30308&wire=5

or contact Joseph E. Levi, Esq. either via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500. There is no cost or obligation to you.

Cannot view this image? Visit: https://images.newsfilecorp.com/files/7091/132063_146703_logo.jpg



Cannot view this video? Visit:
https://www.youtube.com/watch?v=7icwfSu4Csc

Outset Medical, Inc. NEWS - OM NEWS

CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (1) the Company's flagship product, Tablo Hemodialysis System ("Tablo"), would require an additional 510(k) application to be filed with The United States Food and Drug Administration ("FDA"), as defendants had "continuously made improvements and updates to Tablo over time since its original clearance"; (2) as a result, the Company could not conduct a human factors study on a cleared device in accordance with FDA protocols; (3) the Company's inability to conduct the human factors study subjected the Company to the likelihood of the FDA imposing a "shipment hold" and marketing suspension, leaving the Company unable to sell Tablo for home use; and (4) as a result, defendants' positive statements about the Company's business, operations, and prospects were materially false and misleading and /or lacked a reasonable basis at all relevant times.

WHAT THIS MEANS TO SHAREHOLDERS: If you suffered a loss in Outset Medical during the relevant timeframe, you have until September 6, 2022 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. Discuss your rights with our legal team without cost or obligation.

PROTECT YOUR FINANCIAL INTERESTS: Complete this brief submission form https://www.zlk.com/pslra-1/outset-medical-inc-information-request-form?prid=30308&wire=5 or call 212-363-7500 to discuss the case.

WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/132063

info